CSL faces the prospect of a second strike in two years this week when the board fronts angry investors after a poorly received restructure wiped billions of dollars from the biotechnology giant’s valuation.
A second strike – when more than 25 per cent of votes are cast against the company’s proposed executive pay plan – paves the way for a second ballot on whether to spill the board led by chairman Brian McNamee.
Loading…
